Weekly Anti-CD30 ADC Dosing for Hematologic Cancer Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CD30-expressing hematologic cancers, such as Hodgkin lymphoma, are associated with significant morbidity and limited long-term disease control, with a lack of well-tolerated and efficacious options for patients who relapse or are ineligible for salvage therapy.
Innovation Solution
A weekly dosing regimen of the anti-CD30 antibody-drug conjugate cAC10-MC-vc-PAB-MMAE at doses of 0.8 mg/kg to 1.2 mg/kg provides a high response rate with an acceptable tolerability profile, allowing for multiple objective responses within a short time period and serving as a monotherapy without increasing adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multi-agent chemotherapy and radiotherapy are used to treat Hodgkin lymphoma, then durable remission rate is improved (approximately 70%), but patient morbidity increases significantly (secondary malignancies, cardiac disease, infertility)
Solution Approach 1:
The patent extracts the cytotoxic function from traditional multi-agent chemotherapy and concentrates it into a single antibody-drug conjugate (brentuximab vedotin). This monoclonal antibody specifically targets CD30-expressing Hodgkin lymphoma cells and delivers the cytotoxic agent MMAE directly to the tumor, eliminating the need for multiple chemotherapy agents and their associated toxicities while maintaining therapeutic efficacy
Solution Approach 2:
The patent introduces a monoclonal antibody as an intermediary carrier that specifically binds to CD30 on Hodgkin lymphoma cells. This antibody acts as a targeted delivery system, transporting the cytotoxic drug MMAE selectively to tumor cells while sparing healthy tissues, thereby improving the therapeutic index and reducing systemic side effects compared to traditional chemotherapy
2Reliability
If salvage chemotherapy and autologous stem cell transplant are used for relapsed patients, then disease control is attempted, but morbidity remains significant and long-term disease control is limited
Solution Approach 1:
The patent employs a disposable, targeted therapeutic approach using antibody-drug conjugate that acts directly on CD30-expressing cells. This single-agent therapy provides sustained response in relapsed patients without requiring the complex, high-morbidity procedures of salvage chemotherapy and stem cell transplant, offering a less invasive alternative with durable disease control
3Productivity
If weekly dosing regimen of anti-CD30 antibody-drug conjugate is administered, then response rate increases (multiple complete responses within 8 weeks), but dosing frequency and total dose increase
Solution Approach 1:
The patent implements a weekly dosing schedule that maintains continuous therapeutic pressure on CD30-expressing Hodgkin lymphoma cells. This frequent dosing ensures sustained drug levels and continuous target engagement, leading to rapid and multiple complete responses within 8 weeks, overcoming the limitations of less frequent dosing regimens
Data Source
AI summary
Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula I.:or a pharmaceutically acceptable salt thereof;wherein:mAb is an anti-CD30 antibody unit,S is a sulfur atom of the antibody,A- is a Stretcher unit, andp is from about 3 to about 5.